Brokerages expect Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) to report $2.20 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Ekso Bionics Holdings’ earnings. The highest sales estimate is $2.28 million and the lowest is $2.11 million. Ekso Bionics Holdings posted sales of $1.55 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 41.9%. The company is scheduled to announce its next quarterly earnings results on Thursday, July 27th.
According to Zacks, analysts expect that Ekso Bionics Holdings will report full-year sales of $2.20 million for the current fiscal year, with estimates ranging from $9.81 million to $10.17 million. For the next fiscal year, analysts forecast that the company will post sales of $19.56 million per share, with estimates ranging from $14.36 million to $24.75 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Ekso Bionics Holdings.
Ekso Bionics Holdings (NASDAQ:EKSO) last issued its quarterly earnings data on Tuesday, May 9th. The company reported ($0.38) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.41) by $0.03. The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.38 million. Ekso Bionics Holdings had a negative return on equity of 788.27% and a negative net margin of 392.15%.
EKSO has been the topic of several research analyst reports. Zacks Investment Research lowered Ekso Bionics Holdings from a “buy” rating to a “hold” rating in a research note on Friday, June 16th. B. Riley restated a “buy” rating and issued a $4.00 price objective on shares of Ekso Bionics Holdings in a research note on Wednesday, May 10th.
Ekso Bionics Holdings (NASDAQ:EKSO) traded up 18.49% during mid-day trading on Thursday, reaching $1.73. The company’s stock had a trading volume of 1,231,470 shares. Ekso Bionics Holdings has a 52-week low of $0.99 and a 52-week high of $6.55. The company has a 50 day moving average of $1.87 and a 200-day moving average of $2.89. The stock’s market cap is $44.35 million.
An institutional investor recently raised its position in Ekso Bionics Holdings stock. Carl Domino Inc boosted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 262.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 46,966 shares of the company’s stock after buying an additional 34,008 shares during the period. Carl Domino Inc owned approximately 0.21% of Ekso Bionics Holdings worth $193,000 at the end of the most recent reporting period. Institutional investors own 4.41% of the company’s stock.
Get a free copy of the Zacks research report on Ekso Bionics Holdings (EKSO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
